关于山东鲁抗医药股份有限公司 2024 年度向特定对象发行 A 股股票 之 上市保荐书 保荐机构 （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年十二月 山东鲁抗医药股份有限公司 上市保荐书 上海证券交易所： 中国国际金融股份有限公司（以下简称"保荐机构"、"保荐人"、"本机构"或 "中金公司"）接受山东鲁抗医药股份有限公司（以下简称"鲁抗医药"、"发行人" 或"公司"）的委托，就发行人 2024 年度向特定对象发行 A 股股票并在主板上市事项 （以下简称"本次发行"）出具本上市保荐书。 保荐机构及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《证券发行上市保荐业务管 理办法》（以下简称"《保荐办法》"）、《上市公司证券发行注册管理办法》（以下 简称"《注册管理办法》"），以及《上海证券交易所股票上市规则》（以下简称"《上 市规则》"）、《上海证券交易所发行上市审核规则适用指引第 2 号——上市保荐书内 容与格式》（以下简称"《指引第 2 号》"）等法律法规和中国证券监督管理委员会（以 下简称"中 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600789 证券简称：鲁抗医药 公告编号：2025-061 山东鲁抗医药股份有限公司 关于向特定对象发行股票发行结果暨股本变动公告 预计上市时间：山东鲁抗医药股份有限公司（以下简称"公司""本公司""鲁 抗医药"或"发行人"）向特定对象发行人民币普通股（A 股）股票（以下简称"本次 发行"）对应的 146,520,146 股已于 2025 年 12 月 29 日在中国证券登记结算有限责任公 司上海分公司办理完毕登记、托管及限售手续。公司本次发行新增股份为有限售条件流 通股，将于限售期届满后的次一交易日起在上海证券交易所（以下简称"上交所"）上 市流通交易，如遇法定节假日或休息日，则顺延至其后的第一个交易日。 资产过户情况：本次发行的股票全部以现金认购，不涉及资产过户情况。 一、本次发行概况 （一）本次发行履行的相关程序 1、本次发行履行的内部决策程序 2024 年 12 月 20 日，发行人召开 2024 年第十一届董事会第五次会议、第十一届监 事会第 ...

证券代码:600789 证券简称:鲁抗医药 公告编号:2025-060 （公告编号：2022-066）、《鲁抗医药关于公司南厂区土地办理完成移交手续 暨进展公告》（公告编号：2024-034）。 山东鲁抗医药股份有限公司 关于收到南厂区土地收储补偿款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、情况概述 山东鲁抗医药股份有限公司（以下简称"公司"）分别于2022年8月10日召 开第十届董事会第十二次（临时）会议、2022年9月15日召开2022年第一次临时 股东大会，审议通过了《关于政府收储部分国有土地使用权的议案》，同意公 司与济宁市自然资源和规划局签订《济宁市国有建设用地使用权收回合同》， 将公司南厂区五宗国有建设用地237100平方米（折合约355.65亩，其中含原山 东鲁抗医药集团有限公司土地14675平方米，委托本公司统一办理）进行收储， 并支付公司土地收储包干补偿费36039.60万元（其中含原山东鲁抗医药集团有 限公司土地包干补偿费2282.256万元，系公司接受山东鲁抗医药集团有限公司 委托代 ...

格隆汇12月30日｜鲁抗医药公告称，公司南厂区五宗国有建设用地被收储，土地收储包干补偿费3.60亿 元。公司已完成土地整体移交，2025年12月30日收到第五笔土地补偿款1000万元，截至目前累计收到补 偿款1.32亿元，尚未收到补偿款余额2.28亿元。公司将按规定对补偿款进行会计处理，以审计结果为 准。 ...

Core Viewpoint - The company, LuKang Pharmaceutical (600789.SH), announced that its subsidiary, Shandong LuKang Pharmaceutical Group Sait Company, received a drug registration certificate from the National Medical Products Administration for Finasteride tablets, which is approved as a generic drug under the new registration classification 4 and has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The drug Finasteride is a synthetic steroid compound that specifically inhibits the enzyme type II 5α-reductase, which is involved in the metabolism of testosterone to dihydrotestosterone (DHT) [1] - Finasteride is effective in reducing DHT levels in blood and prostate, which is crucial for treating benign prostatic hyperplasia (BPH) [1] - The 1mg specification of Finasteride is indicated for the treatment of male pattern hair loss, promoting hair growth and preventing further hair loss, while the 5mg specification is used for treating and controlling BPH and preventing urinary system events [1]

Core Viewpoint - The announcement indicates that LuKang Pharmaceutical's subsidiary, Shandong LuKang Pharmaceutical Group Sait Company, has received a drug registration certificate for Finasteride tablets, marking a significant milestone in the company's product portfolio and regulatory compliance [1] Group 1: Product Approval - The drug registration certificate for Finasteride tablets was issued by the National Medical Products Administration, with approval numbers 2025S03900 and 2025S03901 [1] - Finasteride is classified as a Category 4 generic drug, having passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Drug Mechanism and Applications - Finasteride acts as a specific inhibitor of the enzyme 5α-reductase type II, which is involved in the metabolism of testosterone to dihydrotestosterone (DHT) [1] - The 1mg formulation is indicated for the treatment of male pattern baldness, promoting hair growth and preventing further hair loss [1] - The 5mg formulation is used for the treatment and management of benign prostatic hyperplasia (BPH), helping to reduce prostate size and improve urinary flow and symptoms related to prostate enlargement [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Sait Company, has received a drug registration certificate for Finasteride tablets from the National Medical Products Administration, which is classified as a Category 4 generic drug and has passed the consistency evaluation [1] Group 1: Product Approval - The drug Finasteride is available in two specifications: 5mg and 1mg, and it is known to reduce DHT levels in blood and prostate [1] - The approval of this drug is expected to help the company optimize its product structure [1] Group 2: Market Sales Data - The total sales in hospitals across the country for the years 2022 to the first half of 2025 are approximately 469 million, 483 million, 490 million, and 343 million respectively [1] Group 3: Market Uncertainties - The production and sales of the drug are subject to uncertainties influenced by policies and market factors [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600789 证券简称：鲁抗医药 公告编号：2025-059 山东鲁抗医药股份有限公司 关于控股子公司获得药品注册证书的公告 二、药品研发及市场情况 近日，山东鲁抗医药股份有限公司（以下简称"公司"）控股子公司山东鲁 抗医药集团赛特有限责任公司（以下简称"赛特公司"）收到国家药品监督管理 局颁发的关于非那雄胺片（以下简称"该药品"）的《药品注册证书》（批件号： 2025S03900、2025S03901），该药品是按照新注册分类 4 类获批的仿制药，视为 通过仿制药质量和疗效一致性评价。现将相关情况公告如下： 一、药品证书基本信息 药品名称：非那雄胺片 剂型：片剂 规格：5mg、1mg 原药品批准文号：国药准字 H20256366、国药准字 H20256367 药品注册标准编号：YBH32382025 注册分类：化学药品 4 类 生产企业：山东鲁抗医药集团赛特有限责任公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注 ...

Core Viewpoint - The approval of Finasteride tablets by the National Medical Products Administration is a significant milestone for the company, enhancing its product portfolio and addressing market demand [1] Group 1: Product Approval - The company's subsidiary, Sait Company, received a drug registration certificate for Finasteride tablets, classified as a Category 4 generic drug [1] - The drug has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Product Specifications and Uses - The 1mg specification is intended for the treatment of male pattern baldness, promoting hair growth and preventing further hair loss [1] - The 5mg specification is used for treating and controlling benign prostatic hyperplasia (BPH), helping to reduce prostate size and improve urinary flow and related symptoms [1] Group 3: Research and Development Investment - Sait Company has invested approximately RMB 3.5 million in research and development for this product [1] Group 4: Market Impact - The approval is expected to positively impact the company's product structure optimization, maintain stable production capacity, and meet market demand [1] - However, the production and sales of the drug are subject to uncertainties influenced by policies and market conditions [1]

Group 1 - Company Shandong Lukang Pharmaceutical Group Saiter Co., Ltd. received a drug registration certificate for Finasteride tablets from the National Medical Products Administration, indicating approval as a generic drug that meets quality and efficacy consistency evaluation [1] - Finasteride is a synthetic steroid compound that acts as a specific inhibitor of the enzyme 5α-reductase type II, which converts testosterone to dihydrotestosterone (DHT), playing a significant role in benign prostatic hyperplasia (BPH) [1] - The 1mg specification of Finasteride is indicated for the treatment of male pattern baldness, promoting hair growth and preventing further hair loss, while the 5mg specification is used for treating and controlling BPH, improving urinary flow and related symptoms [1] Group 2 - There are currently 46 production approvals for Finasteride tablets in China, with 24 companies holding 29 approvals that have passed or are deemed to have passed the quality and efficacy consistency evaluation [2] - The total sales of Finasteride tablets in hospitals across China for the years 2022, 2023, 2024, and the first half of 2025 are approximately CNY 469 million, CNY 483 million, CNY 490 million, and CNY 343 million respectively [2] - Since the start of research and development, Saiter Company has invested approximately CNY 3.5 million in R&D (unaudited) [2]